New drug shows promise for dangerous pancreatitis complication

NCT ID NCT03401190

Completed Disease control Sponsor: CalciMedica, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called CM4620-IE in 21 people with severe pancreatitis that caused body-wide inflammation (SIRS). The goal was to see if the drug is safe and to find the best dose for future studies. Participants received the drug plus standard care or standard care alone. The study was small and not designed to prove the drug works, but to gather information for larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE PANCREATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute pancreatitis pancreatitis Systemic Inflammatory Response Syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE PANCREATITIS SYSTEMIC INFLAMMATORY RESPONSE SYNDROME

Contacts and locations

Locations

Ben Taub (Baylor College of Medicine)

Houston, Texas, 77030, United States
Detroit Receiving Hospital (Wayne State)

Detroit, Michigan, 48201, United States
Hennepin County Medical Center

Minneapolis, Minnesota, 55415, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
MetroHealth (Case Western)

Cleveland, Ohio, 44109, United States
Regions Hospital

Saint Paul, Minnesota, 55101, United States
Riverside Methodist

Columbus, Ohio, 43214, United States
Sinai-Grace Hospital (Wayne State)

Detroit, Michigan, 48235, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.